Ecoppia Lands a 181.25 MWac Project in Chile With Global Player ENGIE
27.2.2023 13:35:00 EET | Business Wire | Press release
Ecoppia (TASE: ECPA), the world’s leader in robotic cleaning solutions for photovoltaic solar, announced another significant collaboration with ENGIE, in its 181.25 MWac/199.8MWdc Coya Solar PV Plant in Chile’s Antofagasta region, the energy company’s largest project in northern Chile.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230227005251/en/
Ecoppia T4 Robotic Cleaning Solutions (Photo: Business Wire)
ENGIE’s collaboration with Ecoppia marks the continuation of a successful relationship between the two companies, with their fourth joint project in different regions of the world. The project is expected to generate 7.2M US$ in revenue for Ecoppia over the course of the projects’ lifecycle.
The Coya Solar PV Plant is located in one of the driest regions in the world. Ecoppia’s water-free robotic cleaning solutions are ideal for the challenges the region presents, as they allow effective, frequent, and autonomous cleaning, in areas with water scarcity and high soiling. Ecoppia’s advanced cloud-based platform allows continuous monitoring and remote management of the robots, as well as an advanced preventive maintenance program – demonstrating the highest availability rates in the market for a decade.
Ecoppia has recently opened its South American office, expanding its local support and addressing the massive demand in the region. “South America is a fast-growing region for renewable energy, and Ecoppia is excited to play such a vital role in ensuring high energy outputs of solar sites despite the local challenges,” says Ecoppia’s CEO, Jean Scemama. “We are happy to collaborate with ENGIE once again, as ENGIE is a forward-thinking company that understands automation is a necessity for large-scale site management, as they know our solutions help IPPs reach lower LCOE.”
About Ecoppia
For nearly a decade, with over 16GW of signed agreements, Ecoppia has been the pioneer and world leader in robotic cleaning solutions for PV. Offering a cloud-based platform and a suite of advanced solutions, Ecoppia’s fully autonomous robots cost-effectively maximize the performance of utility-scale PV sites all over the world. Remotely managed and controlled, the Ecoppia platform allows solar sites to maintain peak performance with minimal costs and human intervention. The company is a publicly traded company with offices in Asia, the Middle East, Europe and LATAM.
Ecoppia in Numbers
+ 3,900MW deployed / under deployment
+ 16,000MW signed agreements
+ 30 large scale projects in 4 continents
+ 8 billion panels cleaned
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230227005251/en/
Contact information
Michelle Harel
Marketing Director
mharel@ecoppia.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom